Innoquest Diagnostics

QUEST FOR H E A LT H Following a recent merger, Innoquest Diagnostics is moving forward as one in pursuit of transformative healthcare.

Ginny Foo, CEO, gives us the details Writer: Jack Salter | Project Manager: Callam Waller

Whilst the medical diagnostics industry has always been robust and resilient, the COVID-19 pandemic saw a sea change in focus on diagnostics.”

At the forefront of this shifting dynamic is Innoquest Diagnostics (Innoquest), whose CEO, Ginny Foo, believes there has never been a more exciting time to be in the industry.

Innoquest was officially launched in March 2021 as a merger of Quest Laboratories (Quest) and Innovative Diagnostics (IDPL), both 2 | APAC Outlook issue 56

long-established in Singapore having been founded in 1995 and 1996, respectively.

Whilst the Innoquest brand is still in its infancy, the actual origins of the lab therefore go back more than 27 years.

“The merger between Quest and IDPL was complicated by the long history of the two labs, the multiple overlapping clients, clinics and test/ profile codes, and the different laboratory information systems (LIS) and instrument platforms (LIP) used,” Foo informs us.

“The Innoquest team are truly unsung heroes who put in countless hours to build the lab that we see today. There were endless issues and hurdles that we needed to overcome to smoothen our workflow and streamline our processes; I also wish to thank our loyal clients who stuck with us throughout.”

Innoquest is proud to serve clinicians, hospitals, medical centres and their patients, as well as nonprofit organisations, through the deployment of advanced diagnostic

Get answers. Keep moving.

From the leader in COVID-19 testing—solutions you can trust for the information you need In a time when getting answers quickly is critical, we’ve responded with solutions to help keep the world moving forward. We deliver: • Proven COVID-19 testing solutions for accurate, trusted results • Reliable supply from a single source for uninterrupted testing • Worldwide service and support to get—and keep—testing up and running And we’ll continue to anticipate evolving testing needs and proactively developing innovative solutions to address future challenges.

Thermo Fisher Scientific is involved in more than 50% of global COVID-19 testing, helping to enable greater access to fast, reliable, trusted answers.

So the world can keep moving.

Find out more at thermofisher.com/covid19 For Emergency Use Only. For prescription use only. For in vitro diagnostic use. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL24450 1020

INNOQUEST DIAGNOSTICS HEALTHCARE

COVID-19 RESPONSE

testing methods, supported by a wealth of industry expertise and ground-breaking technology.

Operating from seven facilities in Singapore, Innoquest’s main laboratory at Starhub Green is installed with the Roche total laboratory automation (TLA) system,

INNOQUEST DIAGNOSTICS AT A GLANCE VISION: To be the eminent innovator and leader in advancing new frontiers in medical testing and diagnostics.

MISSION: To transform healthcare and improve the human condition.

PURPOSE: To save and improve every patient’s life.

VALUES: • The pursuit of excellence • Care for others • Innovation that impacts • Trust with integrity

4 | APAC Outlook issue 56

capable of performing tests for more than 15,000 patients a day.

“What we achieved in 2021 was truly amazing. We managed to merge two huge laboratories into one, renovated and expanded the lab space so that we could change our LIP, upgraded our LIS to a newer version, and continued to improve our lab processes.”

With the installation of multiple Roche TLA systems at Innoquest’s laboratories, the company has been able to enhance the capacity, accuracy, and quality of its testing capabilities.

The patient’s sample is placed into the TLA system, which reads the barcode on the back of the sample tube and detects what tests to run.

Once tested, the sample goes into refrigerated storage at the stockyard; if clinicians wish to add a test, the request is relayed to the LIS and the sample is automatically retrieved from the stockyard.

“For abnormal results, repeat criteria are keyed into the system.

Samples that require a repeat are picked up automatically by the system and transported to the analyst, minimising human intervention and removing human error almost completely from the entire analytical process,” Foo explains.

The company’s extensive network of laboratories offer a wide range of in-vitro diagnostic (IVD) tests across laboratory medicine, to help detect diseases or conditions and to monitor the health of patients.

“We provide a full range of IVD tests, which include allergy testing, biochemistry, anatomical pathology, haematology, immunology, microbiology, molecular and much more.

“100 percent of cancers are diagnosed by pathologists, and 70 percent of medical treatments, diagnoses and discharge decisions are based on pathology test results.

Everyone from birth to old age uses pathology at some point in their lives to determine the status of their health – that is how important and crucial medical diagnostics are to the healthcare industry,” emphasises Foo. At the peak of COVID-19 testing, Innoquest had about 300 members of staff in the COVID-19 labs and logistics department, providing a 24/7 roundthe-clock service to clinics, hospitals, and swab collection sites.

“Our core business comprises over 440 employees, so altogether we had around 740 people working under the Innoquest brand by the end of 2021.

Now, we are slowly ramping down the COVID-19 labs and redeploying some personnel to our other laboratories.”

In response to the urgent need to boost Singapore’s COVID-19 testing capacity, the company worked alongside the Ministry of Health to build five COVID-19 testing laboratories in 2020 within the space of nine weeks.

To date, more than 3.8 million COVID-19 swab tests have been performed by Innoquest, who had to quickly pivot to perform enough PCRs to cater to the mass testing requirements of the nation.

“The last two years have taught us many things in terms of hazard preparedness. Innoquest has stepped up to the challenge and contributed

Expand the possibilities Real-time PCR for the molecular detection of infectious disease pathogens Grow your capabilities with PCR-based RUO panels that enable accurate and efficient results. Our extensive library of predesigned Applied Biosystems™ assays helps laboratories provide sensitive and scalable insights. And thanks to our global supply chain, you can be confident that you’ll have access to what you need for any routine or specialized testing.

Learn more at thermofisher.com/pathogendetection For Research Use Only. Not for use in diagnostic procedures. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL020355 0622

INNOQUEST DIAGNOSTICS HEALTHCARE

APAC OUTLOOK: HOW DID YOU BECOME INTERESTED IN THE HEALTHCARE INDUSTRY?

GINNY FOO, CEO: “My first degree was in Food Science at the University of Guelph, Canada, but I became interested in healthcare when my mother was hospitalised in the late 1980s.

“I came across the hospital laboratory whilst visiting her, and went in to speak with the Laboratory Manager. He asked me to send my CV, which I did, and I got my first job as a medical technologist at the Mount Elizabeth Hospital lab in 1989.

“I’ve been in the healthcare industry since, and had to pursue another degree in Medical Science in order to advance further in the sector. I completed a twinning programme with the Curtin University of Technology in Perth, Australia, and obtained my BSc in Medical Science in February 2005 after just over a year on the programme.”

significantly to the nation’s COVID19 testing capacity throughout the pandemic. After going through this exercise, we are now more prepared to face any such pandemics again in the future,” Foo acclaims.

As a result, Innoquest laboratories 6 | APAC Outlook issue 56

went from performing 200 molecular tests per day to several thousand at the height of the pandemic, and since April 2020 has issued over 10 million patient results.

Given the huge number of samples that have been processed, the pandemic has unsurprisingly been an extremely busy and stressful time for Innoquest.

“The mental and physical stress on our lab staff was enormous, as they had to ensure they did not get infected with COVID-19 and transmit the virus to their family members.

Some staff were staying away from their family members for months whilst they were working in the laboratory, just to keep their families safe,” reveals Foo. “Many staff stepped up from their usual job scope to help with the COVID-19 testing process, such as driving vans to pick up samples from collection sites or helping to sort out samples for testing at the labs.

“With the right processes in place, we are very glad that after two years of intense testing, no one at the lab has been infected,” she continues.

DIGITAL TRANSFORMATION Innoquest recently automated its microbiology department, by investing in the latest MALDITOF mass spectrometry for the identification and diagnosis of microbes.

Prior to the MALDI-TOF system, it would take at least 72 hours for a clinician to receive indicative information on the result of the test. As microbiology is often a decisive factor in the prescription of antibiotics, this lengthy turnaround time ran the risk of increasing antibiotic usage.

With the MALDI-TOF system in place, Innoquest is able to provide a turnaround time of less than 48 hours and an overall accuracy of 95 percent at species level, enabling fast and correct treatments for patients.

“We hope this will assist Singapore in reducing the unnecessary use of antibiotics and improve antibiotic stewardship,” outlines Foo. This automated system ties in with Innoquest’s ongoing digital transformation initiatives, as it embraces a world of electronic orders, e-billings, e-payments and digitalised reports. Not only does this enable patients and doctors to receive results quicker, but it will also enhance the overall patient journey and subsequently result in better care.

“We will no longer work in the background, but instead take on an enabling role in bringing quality care to patients in collaboration with our healthcare partners.”

Providing high quality, accessible, and affordable diagnostics is at the heart of Innoquest, and can’t be achieved without unparalleled customer service and the latest technologies.

Partners rely on Innoquest to assist in their medical diagnoses, and the company is committed to providing clients with a memorable, positive end-to-end experience. In this regard, Innoquest is working with healthcare platform BioMark to further enhance the digitalisation of pre- and postanalytical processes.

“Our goal in the next two to three years is to do away with pen and paper, and have all of our lab orders and reports issued electronically.

BioMark and the Innoquest IT team have to perform API beta testing, so we should be rolling out the application to our clients very soon.”

In Singapore, BioMark has partnered with Innoquest’s 2,500 clinics, storing lab results from nearly two million patients.

BioMark acts as the conduit between Innoquest, doctors and patients. Broadly speaking, BioMark compiles blood and pathology reports, and displays them to doctors and patients through its own innovative platform.

Extending molecular testing capabilities following COVID-19

T

he World Health Organization declared COVID-19 a pandemic in early March 2020. In advance of the announcement, Thermo Fisher Scientific had been working on developing a PCRbased COVID-19 diagnostic test to detect SARSCoV-2. In record time, the TaqPath COVID-19 test kit was available worldwide to meet diagnostic testing demands and enable surveillance efforts in over 140 countries.

PCR-based COVID-19 molecular testing received rapid adoption around the world because regulatory bodies understood the need for accurate and gold standard technology to combat the deadly pandemic. As a result, new and existing clinical testing laboratories increased their sample throughput capabilities by acquiring more real-time PCR instrumentation, bringing molecular testing to an unprecedented high.

Expand the possibilities

The benefits of molecular testing are high analytical sensitivity, offering the ability to accurately detect targets with low copy numbers, and specificity, allowing detection and differentiation between closely related targets due to robust chemistry.

Syndromic panels offer the ability to test for a broad range of pathogens from the same sample, which provides clinicians with information for a betterinformed diagnosis and more appropriate treatment decisions. Syndromic panels can also represent a powerful tool for understanding antimicrobial resistance, which is key to proper antimicrobial stewardship.

Molecular testing has revolutionized how healthcare providers diagnose and treat infections. Improving disease management can have profound effects on limiting risks of antimicrobial resistance, direct patient care and their subsequent outcomes, and the costs to the healthcare system.

As we look ahead, Thermo Fisher Scientific is fully committed to developing and marketing IVD devices for molecular diagnostics. We have over 25 years of qPCR instrument and over 10 years of clinical instrument manufacturing experience and an equally longstanding history of developing PCR assays.

Our size, scale, and worldwide presence makes us uniquely suited to support all aspects of diagnostic testing solutions.

Real-time PCR for the molecular detection of infectious disease pathogens

Molecular testing is not new and has long been proven to be a powerful technology. Infectious disease testing traditionally requires growing, isolating, and identifying pathogens in culture. This approach is time-consuming and labor-intensive.

In contrast, culture-independent molecular testing has excellent performance characteristics, Grow your capabilities with PCR-based RUO shortens panels that enable accurate and efficient turn-around times, and offers integrated workflows Our mission is to enable our customers to make the results. Our extensive library of predesigned Applied Biosystems™ assays helps that require limited technical expertise. Infectious world healthier, cleaner, and safer. We are here to laboratories sensitive insights. to our our customers global supply diseaseprovide areas that benefitand fromscalable molecular testing And thanks support by accelerating life sciences include respiratory tract infections, gastrointestinal research, increasing lab productivity, and improving chain, you can be confident that you’ll have access to what you need for any routine or infections, sexually transmitted infections, urinary health through accurate diagnostics and lifespecialized testing. tract infections, and women’s health, among others. changing therapies.

To learn more, visit thermofisher.com/pathogendetection.

Learn more at thermofisher.com/pathogendetection

INNOQUEST DIAGNOSTICS HEALTHCARE

Biomed Global As a leading organization in the biomedical and life sciences industry, Biomed Global offers a holistic range of innovative and cuttingedge solutions for healthcare in the Southeast Asia Region.

From market research to business development, and technical service, we extend our in-depth knowledge and experience to empower our partners to raise healthcare standards globally.

We believe in the power of bringing people and medical innovations together to shape the future of the healthcare industry and improve the quality of life. Our team of 250+ is constantly working hard and smart to deliver our solutions throughout the region and coupled with more than 20 years of experience in this industry, makes us a critical part of the diagnostic testing ecosystem in the region.

Clinics and healthcare providers can therefore effectively monitor their patients’ wellbeing, and flag those who need follow-up consultations or tests. The platform allows for real-time results to be viewed by doctors, and with immediate access to results as soon as they are validated in the lab, it enables a much faster turnaround and better service provision.

Likewise, patients are able to make more sense of their lab results and monitor the progress of their health, creating better continuity of care and interaction with doctors.

For example, BioMark’s platform is used in the Philippines by over 10,000 patients for the management of diabetes, in partnership with Sanofi.

This real-world, real-time monitoring platform has resulted in dramatic improvements to the HbA1c results in diabetics, and in both quantitative and qualitative metrics across the board, an 8 | APAC Outlook issue 56

indicator of the long-term reduction in complications from diabetes.

“BioMark’s services intend to add value for patients, by placing doctors at the centre of the equation in order to provide better care,” Foo says.

GENETIC TESTING IS THE FUTURE Innoquest is also working closely with sister genomic diagnostics company, LifeStrands, to drive the adoption of clinical genomics and to advance precision medicine in Southeast Asia.

LifeStrands intends to research and develop new assays tailored to the Southeast Asian population, and its medical needs by partnering with best-in-class companies and research institutions to develop expertise in Singapore through tech transfers.

The three segments that LifeStrands will be concentrating on from the start will be oncology,

Our cooperation with Innoquest began in 1996 with one of its subsidiaries Gribbles, and together we have grown from strength to strength over the decade. Both our organizations have gone through rebranding exercises to become the well-respected brands we have established today.

We are proud to have worked together on multiple projects to improve patient care and lower the cost of testing such as COVID-19, Blood Banking, Allergy Testing, and Microbiology Testing.

Our COVID-19 project is particularly noteworthy for its scale and speed of deployment throughout the Innoquest network which greatly improved the pandemic situation. We continue to work on many more such projects which promise to deliver greater impact than ever before.

www.biomed-global.com

Healthcare Solutions

Biomed Global is a renowned brand for healthcare solutions in the clinical diagnostics and lifesciences space across Southeast Asia. As the exclusive distributor for certain product lines of Becton Dickinson, ThermoFisher, Biorad, Bruker, and numerous other leading diagnostics organizations, our portfolio breadth is among the widest in the region.

Bruker Bruker MALDI Sirius Biotyper System identifies microorganisms using MALDI-TOF (Matrix-Assisted Laser Desorption/ Ionization Time of Flight) mass spectrometry to measure highly abundant proteins that are found in all microorganisms.

ICatcher Make early cancer detection possible with iCatcher – A platform designed to extract cfDNA & cfRNA from up to 4mL of blood or plasma.

MGI High speed, high flexibility, and ultra-high throughput turbocharge your sequencing.

Tissue Gnostics A solution provider for Precision Medicine / Next-Generation Digital Pathology and provides fully integrated cutting-edge tissue cytometers.

Our team is also constantly on the lookout for new and innovative healthcare solutions which can bring substantial transformation to the healthcare landscape and raise the standards of healthcare in our markets.

We take pride in our wealth of expertise, which is critical to ensure the needs of our customers', such as Innoquest, are well met at the highest levels of customer satisfaction possible. We also are on the journey to becoming an organization which considers wellbeing one of the pillars of growth for the future.

www.biomed-global.com

Werfen IL coagulation All ACL TOP systems are optimized to run with a comprehensive panel of HemosIL reagents, they offer complete disease-state management. The broad test menu provides flexible solutions for both routine and specialty testing. The same reagents on all ACL TOP systems mean true standardization throughout the lab.

INNOQUEST DIAGNOSTICS HEALTHCARE

reproductive health, and inherited disorders.

The importance of developing an oncological test that can screen and detect the early onset of cancer cannot be overemphasised, and this is now possible through genetic testing, which detects genetic risk factors and links them to a wide spectrum of cancers. Targeted therapy or precision medicine also guides clinicians to a more patientcentric approach and the most effective treatments.

Reproductive health is another very important segment, in view of more and more couples starting families in their mid or late 30s.

Non-Invasive Prenatal Testing (NIPT) screens pregnant women to test for trisomies 21, 18, and 13, for the highly accurate detection of Down’s, Edwards’, and Patau’s Syndrome.

“Other reproductive screenings include the carrier screening for couples planning to start a family.

This is a comprehensive test to detect genetic disorders in one or both parties, and has the power to detect diseases causing mutations in over 2,000 genes,” Foo notes.

Finally, comprehensive tests can identify inherited risks for at least eight types of cancer based on investigations into personal or family history, as well as hereditary heart conditions based on a patient’s genetic make-up – there is a 50 percent chance of inheriting an autosomal dominant cardiovascular condition from an affected first degree relative.

The test investigates and reports known, affected genes that are linked to a wide variety of cardiovascular disorders. This better informs clinicians and patients on the best management or treatment decisions to make.

“Reproductive health tests such as NIPT screenings and carrier tests are already available, and can be ordered by clinicians. Hereditary disorder testing for oncology, cardiology, and 10 | APAC Outlook issue 56

other rare diseases including the whole exome sequencing are available as send-out tests, but are in the pipeline to be done in-house soon.”

Innoquest strongly believes that genetic testing will be the future of laboratory medicine. Indeed, major advances have been made in the understanding of the human genetic make-up, and laboratory medicine is making big leaps in research to come up with new tests for the prevention and treatment of many diseases.

Previously, only a single gene could be examined at a time, but as technology and molecular biology laboratory techniques have developed, next generation sequencing (NGS) allows for much faster and cheaper sequencing of large portions of DNA, or even the whole genome.

“Within the next few years, we will see genetic testing replace many older methods of predicting prognosis by pairing patients with therapies they will respond to, or by identifying the right dosage of medicine for the best results,” Foo tells us.

“With more advances made in recent years, genetic testing will impact the laboratory space even more by allowing doctors to detect a variety of diseases earlier and therefore administer treatment sooner.

“These advances will be most welcome, especially for complex diseases such as cancer. We also hope to see the cost of genetic tests come down with NGS techniques, and this will make it more affordable for the masses.”

MEDICALLY MANAGED Testament to Innoquest’s quality standards is the company’s dual accreditation from the College of American Pathologists (CAP) and the Singapore Laboratory Accreditation Scheme (ISO 15189).

With a senior management team comprising medical doctors and senior scientists, whose accumulated laboratory experience exceeds 100 years, Innoquest also differentiates

Thermo Fisher Scientific Pharmacogenomics is Ready to Go Mainstream Pharmacogenomics (PGx) is the understanding of how genes impact response to medications. Significant progress has been made to determine the safest, most effective course of treatments. As we deploy more PGx testing, we are better positioned to improve the health of individuals and communities, with the potential to reduce healthcare costs.

“The clinician and patient are better informed when PGx testing is used during medication selection, and more importantly, the medication is more likely going work,” says Manoj Gandhi, Senior Director of Medical and Scientific Affairs for Thermo Fisher Scientific.

To learn more about pharmacogenomics solutions, please visit thermofisher.com/pgx.

Advancelab Advancelab is a team of architects, interior designers, construction personnel, safety managers and scientists that are heavily involved in built environment space. We function in many avenues including: • Architect • Design & build • M & E design • Tender administration • Project management • Facility managers We are who our clients need us to be.

Collaboration is our middle name.

Everything from government level CBRE facilities to Class A Office space - we are comfortable, we are forward thinking and most importantly we are eager.

www.advancelabglobal.com

INNOQUEST DIAGNOSTICS HEALTHCARE

The future of health care includes factoring genetic test results into treatment decisions.

Applied Biosystems™ products help drive pharmacogenomics advancements, and we continue to participate in partnerships to make it accessible for laboratories, employers, and government agencies.

Learn more at thermofisher.com/pgx © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL020213 0522

PG2314-PJT7671-COL020213-GTS-PGx-resize-PrintAd-Global-F.indd 1

5/23/22 10:33 AM

CONSTRUCTION We design everthing from offices to advanced national level laboratories.

Site Assessement Layout Plans Client Briefs Room Cards Seminars Construction Budgets and Estimates Regulatory Approval Tender Documentation & Management Project Management BRUNEI DARUSSALAM

CAMBODJA

INDONESIA

LAOS

MALAYSIA

MYANMAR

PHILIPPINES

SINGAPORE

THAILAND

VIETNAM

U.A.E

+65 6448 8255 info@advancelab.com.sg www.advancelabglobal.com

APAC Outlook issue 56 | 11

INNOQUEST DIAGNOSTICS HEALTHCARE

itself from other competitors as a “medically managed” organisation.

“We always believe that it takes a doctor to understand another doctor.

Our Group CEO, Dr Chris Ting, and COO, Dr Anthony Stanislaus, are both medical doctors,” Foo shares.

“Our expertise allows us to offer the widest selection of tests in-house at very competitive rates, with significantly improved turnaround times compared to sending those tests to a referral lab.”

The supply chain is of equal importance to daily operations at Innoquest, who work closely with partners and suppliers to guarantee no logistical disruption.

“Our partnerships with suppliers also ensure that workflows are optimised, and customisations are built to further enhance and improve on quality and efficiencies,” adds Foo. Innoquest works with sister companies across the region to form strong, long-term partnerships

12 | APAC Outlook issue 56

with key suppliers, which allow the company to continuously improve its operations and services, and be at the forefront of new tests being brought to the market.

It is thanks to these deep supplier relationships that Innoquest has partnered on new initiatives and tests being rolled out in Singapore, and introduced the latest technologies.

The company also works closely with charitable organisations such as SATA CommHealth and the National Kidney Foundation, by providing laboratory services at a competitive price to support their respective community initiatives and events.

Nevertheless, Innoquest intends to develop even more structured and sustainable corporate social responsibility (CSR) practices.

“As mentioned, through our partnership with BioMark, we are working with key clients to adopt digital reports. This will significantly reduce the amount of paper used; we

Biomérieux A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide.

We develop and produce diagnostic solutions that help healthcare professionals quickly and reliably determine a pathology or the source of a contamination and provide them with crucial information for optimal patient care.

Our high-performance solutions are based on three key areas of in vitro diagnostics – Microbiology, Immunoassays and Molecular biology.

www.biomerieux-asean.com

INNOQUEST DIAGNOSTICS HEALTHCARE

BE A GAME CHANGER You can make a difference with the right diagnostics tests that give you the power to fight infectious diseases - and save lives.

Outlook Creative Services

Outlook Publishing’s award-winning in-house team is now utilising its extensive production skills to offer a full and bespoke range of editorial, design and marketing services via its new Outlook Creative Services division.

F O R M O R E I N F O R M AT I O N V I S I T: www.outlookpublishing.com/creative-services

APAC Outlook issue 56 | 13

INNOQUEST DIAGNOSTICS HEALTHCARE

Alliance Biomed Alliance BioMed is an in-vitro diagnostics contract manufacturer based in Singapore.

Our mission, at Alliance BioMed, is to continuously innovate biomedical and biotech solutions in preparation for the future. With a unique capability in life science development & contract manufacturing, we have shaped ourselves to become an indispensable partner for research institutes, diagnostic companies and biotech/med start-ups over the years and transforming groundbreaking life science solutions into commercialisation.

Our robust biomedical production and supply chain strength has made us the dominant supplier of the premium COVID-19 testing solutions to test centres nationwide, including Innoquest.

www.alliance-biomed.com

are currently dispersing more than 400,000 hardcopy reports a month, so one of our key goals in the next two years is to convince more healthcare partners to go digital and make the world more sustainable,” Foo says.

EXCITING RIDE AHEAD Innoquest’s key priorities for the coming year are threefold. First and foremost, the company aims to increase the selection of tests available to doctors in Singapore, including but not limited to genetic testing for the early detection of cancer.

As well as automating pre- and post-analytical processes through digitalisation to improve efficiencies, reduce the environmental impact of 14 | APAC Outlook issue 56

reporting, and provide an unparalleled service to clients, Innoquest will look to enhance the experience of healthcare partners and enable them to provide better, faster, and more accurate care to their patients.

“A key area of improvement we are targeting is the anatomical pathology department. Singapore, like many countries in the world, suffers from a chronic shortage of anatomical pathologists, especially in the private sector,” acknowledges Foo. “In order to keep up with the rising demand of this segment, we will upgrade our anatomical pathology department, beginning with the automation of sample preparation and workflow processes.

“In the medium term, we are

working on installing digital pathology technologies, which will provide more flexibility to accredited pathologists from overseas to read and report on the work in Singapore. Eventually, we will look into the use of artificial intelligence tools to help improve the speed and quality of our results.”

Foo concludes by assuring clients, suppliers and staff of an exciting, fruitful, and successful ride.

“Let’s start dreaming about what we want to see in the next five to 10 years for the laboratory diagnostics industry. We look forward to the day when we will see the lab in its full glory – wouldn’t that be amazing!”

INNOQUEST DIAGNOSTICS Tel: (65) 6235 6950 https://www.innoquest.com.sg

INNOQUEST DIAGNOSTICS HEALTHCARE

RESOLUTE 2.0 The premier turnkey solution for testing centres looking to face the increasing need for PCR testing with confidence.

RESOLUTE 2.0 COVID-19 PCR test kits eliminates the need for RNA extraction, reading clinical results within an hour.

RESOLUTE 2.0

COVID-19 Direct PCR Test Kits Alliance Biomed is one of the few contract development manufacturing organizations that can provide IVD assay development solutions, and production, making us the best option for fullscale manufacturing and commercialization.

Our In-vitro diagnostic contract manufacturing success includes products like RESOLUTE 2.0.

Transforming Possibilities www.alliance-biomed.com

ASSESSING FUTURE CARDIAC RISK IN AN

A S Y M P T O M AT I C P O P U L AT I O N

Abbott’s hsTnI is a cardiac-specific blood test – the first CE marked cardiac-specific biomarker for risk stratification of the apparently healthy population.

As a physician, Abbott’s hsTnI blood test can help you to more accurately stratify an asymptomatic individual’s risk of a future cardiac event. It enables you to better prioritize appropriate care for those at higher risk to help prevent adverse outcomes, and potentially avoid unnecessary investigations and treatments in those at lower risk.

Abbott’s hsTnI can be integrated into daily practice and added to existing patient wellness checks.

To implement cardiac risk stratification of the apparently healthy population using Abbott’s hsTnI test in your practice, please contact your local Abbott representative.

FOR MORE INFORMATION GO TO WWW.COREL ABORATORY.ABBOTT © 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only.

Headquartered in Singapore, BioMedix specializes in distribution of high quality and innovative medical devices, laboratory equipment, test kits and reagents as well as life science products and services which will greatly improve the productivity in the labs and hospitals.

We serve customers across Asia Pacific, providing them with professional service and advice.

Some of the products include: • • • •

Clinical Chemistry Analyser Immunoassay Analyser Haematology Analyser Automated Stainers (Haematology/Gram/TB) • Urea Breath Test Analyser • Hydrogen Breath Test Analyser • Test Kits, Reagents, Chemicals, solvents for Histology, Microbiology, Cytology, etc.

For the full range of products, please visit our website www.biomedix.com.sg +65 6547 5591 sales_enquiries@biomedix.com.sg

APAC Outlook issue 56 | 15

INNOQUEST DIAGNOSTICS StarHub Green 67 Ubi Avenue 1, South Wing #02-08/09, Singapore 408942 Tel: (65) 6235 6950 https://www.innoquest.com.sg/

PRODUCED BY APAC OUTLOOK MAGAZINE